Becton, Dickinson and Company (NYSE:BDX) Price Target Lowered to $170.00 at BofA

Becton, Dickinson and Company (NYSE:BDX) had its price target lowered by equities research analysts at BofA from $177.00 to $170.00 in a research note issued to investors on Friday,MarketScreener reports. BofA’s price target would indicate a potential upside of 15.95% from the company’s previous close.

A number of other analysts have also recently weighed in on the company. Evercore increased their price objective on Becton, Dickinson and Company from $180.00 to $190.00 in a research report on Thursday, May 7th. Zacks Research raised shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Stifel Nicolaus lowered their target price on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Weiss Ratings downgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Finally, Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $182.73.

Becton, Dickinson and Company Stock Down 0.5%

BDX stock opened at $146.62 on Friday. The company has a fifty day moving average price of $150.21 and a 200 day moving average price of $174.25. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The company has a market cap of $40.40 billion, a price-to-earnings ratio of 37.46, a price-to-earnings-growth ratio of 10.46 and a beta of 0.22. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same period in the prior year, the company earned $3.35 earnings per share. The business’s revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Insider Activity

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total value of $166,628.00. Following the completion of the transaction, the executive vice president owned 14,272 shares in the company, valued at approximately $2,161,922.56. This trade represents a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,013 shares of company stock valued at $593,434 over the last 90 days. 0.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several large investors have recently made changes to their positions in the business. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the period. Empowered Funds LLC grew its stake in shares of Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after buying an additional 1,354 shares in the last quarter. United Bank grew its stake in shares of Becton, Dickinson and Company by 23.9% in the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock valued at $887,000 after buying an additional 993 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Becton, Dickinson and Company by 365.1% during the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock valued at $5,491,000 after buying an additional 25,022 shares during the period. Finally, NewEdge Advisors LLC lifted its position in Becton, Dickinson and Company by 34.7% during the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after acquiring an additional 6,058 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.